bovine intestinal alkaline phosphatase

Animal productexperimental

Clinical trial activity

5 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started May 1, 2006 (NCT00727324)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • biap
  • bovine intestinal alkaline phosphatase
  • brescap

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05045833Phase 1Oct 18, 2021Spaulding Clinical Research Inc., Synthetic Biologics
NCT04815993Phase 1Mar 22, 2021Spaulding Clinical Research Inc., Synthetic Biologics
NCT03050476Phase 2/Phase 3 (Phase 3)Feb 1, 2017Aix Scientifics, Alloksys Life Sciences B.V., National University of Singapore, Singapore Clinical Research Institute
NCT01416493Phase 1/Phase 2 (Phase 2)May 1, 2011Aix Scientifics, Alloksys Life Sciences B.V., Maidstone & Tunbridge Wells NHS Trust
NCT00727324Phase 2May 1, 2006AM-Pharma, Charles University, CRM Biometrics GmbH, Sintesi Research Srl, University of Bologna, Vigilex BV
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aix ScientificsFor profit2022011
Alloksys Life Sciences B.V.For profit2222011
Spaulding Clinical Research Inc.For profit2012021
Synthetic BiologicsFor profit2212021
AM-PharmaFor profit1112006
Charles UniversityAcademic/Hospital1012006
CRM Biometrics GmbHFor profit1012006
Maidstone & Tunbridge Wells NHS TrustAcademic/Hospital1012011
National University of SingaporeAcademic/Hospital1012017
Singapore Clinical Research InstituteAcademic/Hospital1012017
Sintesi Research SrlFor profit1012006
University of BolognaAcademic/Hospital1012006
Vigilex BVFor profit1012006
13 organizations
Page 1 / 1